Sei Investments Co. Has $479,000 Holdings in Vanda Pharmaceuticals Inc. $VNDA

Sei Investments Co. trimmed its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 63.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 69,295 shares of the biopharmaceutical company’s stock after selling 120,966 shares during the quarter. Sei Investments Co. owned approximately 0.12% of Vanda Pharmaceuticals worth $479,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of VNDA. AIGH Capital Management LLC acquired a new position in shares of Vanda Pharmaceuticals in the 4th quarter worth approximately $17,626,000. Millennium Management LLC grew its position in Vanda Pharmaceuticals by 220.0% during the 1st quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock worth $9,821,000 after acquiring an additional 1,470,898 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in Vanda Pharmaceuticals by 552.3% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 708,428 shares of the biopharmaceutical company’s stock valued at $6,248,000 after purchasing an additional 599,818 shares in the last quarter. Marshall Wace LLP increased its holdings in Vanda Pharmaceuticals by 945.9% during the 2nd quarter. Marshall Wace LLP now owns 471,720 shares of the biopharmaceutical company’s stock valued at $2,227,000 after purchasing an additional 426,620 shares in the last quarter. Finally, Empire Financial Management Company LLC raised its position in Vanda Pharmaceuticals by 46.2% in the 4th quarter. Empire Financial Management Company LLC now owns 1,108,245 shares of the biopharmaceutical company’s stock valued at $9,775,000 after purchasing an additional 350,154 shares during the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on VNDA. HC Wainwright decreased their target price on Vanda Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Wall Street Zen cut Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. B. Riley Financial reiterated a “buy” rating and set a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a research report on Monday, August 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Friday, July 17th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $13.70.

Vanda Pharmaceuticals Stock Performance

VNDA stock opened at $5.22 on Friday. The company has a 50 day moving average price of $5.67 and a 200 day moving average price of $6.65. Vanda Pharmaceuticals Inc. has a fifty-two week low of $4.27 and a fifty-two week high of $9.94. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.61 and a quick ratio of 1.60. The stock has a market capitalization of $315.62 million, a PE ratio of -1.13 and a beta of 0.64.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.46). The firm had revenue of $50.53 million during the quarter, compared to the consensus estimate of $61.92 million. Vanda Pharmaceuticals had a negative net margin of 127.41% and a negative return on equity of 49.81%. Analysts forecast that Vanda Pharmaceuticals Inc. will post -3 EPS for the current year.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.